![Robert Petit](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Patrimonio netto: 428 000 $ in data 31/05/2026
Robert G.
Petit is currently Senior VP & Head-Early Clinical Development at Orionis Biosciences, Inc. since 2022.
He is Chief Medical & Scientific Officer at OS Therapies, Inc. since 2019.
He is Principal at RGP Biotech, LLC since 2019.
Formerly, Dr. Petit was Director-Medical Strategy at Bristol Myers Squibb Co. from 2005 to 2010.
He was Vice President-Clinical Development at MGI PHARMA, Inc. and Aesgen, Inc. He served as Chief Scientific Officer & Executive VP at Advaxis, Inc. from 2010 to 2019.
He was Chief Scientific Officer at CTx Operations, Inc. and Carisma Therapeutics, Inc. in 2019.
Education includes undergraduate studies at Indiana State University and a doctorate from The Ohio State University.
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
| 22/01/2026 | 200.000 ( 0,45% ) | 428 000 $ | 31/05/2026 |
| Società | Posizione | Inizio |
|---|---|---|
| OS THERAPIES INCORPORATED | Direttore Tecnico/Scientifico/R&S | 01/09/2019 |
RGP Biotech, LLC | Corporate Officer/Principal | 01/06/2019 |
Orionis Biosciences, Inc.
 Orionis Biosciences, Inc. Packaged SoftwareTechnology Services Offers protein interaction platform with direct applications in the discovery of new therapeutics | Corporate Officer/Principal | 01/03/2022 |
| Società | Posizione | Fine |
|---|---|---|
CTx Operations, Inc.
 CTx Operations, Inc. BiotechnologyHealth Technology Develops macrophage-based immunotherapeutic for treatment of cancer | Direttore Tecnico/Scientifico/R&S | 01/12/2019 |
| CARISMA THERAPEUTICS, INC. | Direttore Tecnico/Scientifico/R&S | 01/12/2019 |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 01/01/2010 |
Aesgen, Inc.
 Aesgen, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products | Corporate Officer/Principal | - |
MGI PHARMA, Inc.
 MGI PHARMA, Inc. Pharmaceuticals: MajorHealth Technology Develops. manufactures & markets pharmaceutical and medical products for therapeutic markets | Corporate Officer/Principal | - |
Attive
Inattive
Società nel listino
Aziende private
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
| Aziende private | 11 |
|---|---|
Bristol Myers Squibb Co.
 Bristol Myers Squibb Co. Pharmaceuticals: MajorHealth Technology Manufactures and markets biopharmaceuticals products | Health Technology |
MGI PHARMA, Inc.
MGI PHARMA, Inc. Pharmaceuticals: MajorHealth Technology Develops. manufactures & markets pharmaceutical and medical products for therapeutic markets | Health Technology |
Aesgen, Inc.
Aesgen, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products | Health Technology |
Indiana State University
 Indiana State University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Advaxis, Inc.
 Advaxis, Inc. Pharmaceuticals: MajorHealth Technology Develops immunotherapies for cancer and infectious diseases | Health Technology |
The Ohio State University
 The Ohio State University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Orionis Biosciences, Inc.
Orionis Biosciences, Inc. Packaged SoftwareTechnology Services Offers protein interaction platform with direct applications in the discovery of new therapeutics | Technology Services |
CTx Operations, Inc.
CTx Operations, Inc. BiotechnologyHealth Technology Develops macrophage-based immunotherapeutic for treatment of cancer | Health Technology |
OS Therapies, Inc.
 OS Therapies, Inc. BiotechnologyHealth Technology Operates as a clinical stage therapeutic company engages in development and commercialization of treatments for osteosarcoma | Health Technology |
Carisma Therapeutics, Inc.
 Carisma Therapeutics, Inc. BiotechnologyHealth Technology Develops novel chimeric antigen receptor macrophage and CAR-monocyte technology treatment of non-muscle invasive bladder cancer | Health Technology |
RGP Biotech, LLC |
Seleziona la tua edizione
Tutte le informazioni finanziarie adattate in base al livello nazionale
